Lilly to invest in QurCan as part of genetic medicines deal
Canadian biotech QurCan Therapeutics on Tuesday announced an investment from Eli Lilly NYSE:LLY as part of an exclusive research and collaboration agreement with the Indiana-based pharma giant to develop genetic medicines.The deal focuses on leveraging QurCan’s TERP (Target-Engineered Responsive Po…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.